Last year, the U.S. Food and Drug Administration approved Neffy, a nasal spray form of epinephrine for people who weigh 66 ...

During a severe allergic reaction (anaphylaxis), children who received epinephrine before arriving at the hospital are less ...

ARS Pharmaceuticals, Inc.'s stock soared 25% on strong earnings. Learn about neffy's market potential, risks, and future growth prospects. Read more about SPRY stock here.

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and ...

Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) ...

The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in children aged 4 and above. This is the first emergency allergy treatment ...

For example, the researchers said ... Wargacki also called conventional epinephrine autoinjectors bulky and noted that they must be stored between 68°F and 77°F, creating practical challenges ...

Fear of needles may delay treatment with injectable epinephrine. Children as young as age 10 years can be taught how to use neffy. Payment options are available based on insurance coverage.